2410 Lillyvale Ave Los Angeles, CA
What if your work could improve millions of lives?
127 articles with Grifols
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.
Spanish drugmaker Grifols announced a comprehensive plan Wednesday to improve its efficiency and cost-effectiveness – a move that will reportedly cost some 2,000 U.S. jobs.
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
Grifols announced changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor.
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
GigaGen Inc. announced the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs.
Life Science industries are seeing massive financial fluctuations in how they're handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022
Grifols, S.A. announced that it has filed its 2021 Annual Report on Form 20-F with the United States Securities and Exchange Commission on April 29, 2022.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis
Grifols announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III therapy to treat Sepsis.
Endpoint Health Enters into Global Collaboration and Licensing Agreement with Grifols
Endpoint Health, Inc. announced that the company has entered into a global collaboration and licensing agreement with Grifols, a leading global producer of plasma-derived medicines, under which Endpoint Health will receive exclusive rights to develop and commercialize Antithrombin III in sepsis.
Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals
Grifols, a leading global producer of plasma-derived medicines, announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag™ in 5% and 25% concentrations.
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
Grifols, a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR® Center, where AMBAR® procedure for Alzheimer's disease will be applied to obtain data from clinical practice.
Global Roundup: UK Expands Life Sciences Ecosystem with Formation of We Are Pioneering Group
4/29/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics
- This flagship facility in the principality, the Pyrenees Immunology Research Center (PYIRC), will be one of the few immunology-dedicated research centers in Europe and will serve as an international reference center for the development of treatments for immune system disorders through translational and clinical expertise
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030
Grifols' new commitment of international units (IU) of blood clotting factors for humanitarian aid through the WFH from 2022 to 2030 will more than double its IU donations since 2014, reaching 440 million IU
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021
Grifols, S.A., and announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange Commission on April 9, 2021.
Grifols installs first-ever DG Reader Net analyzer in North America
For the smallest and most specialized laboratories, DG Reader Net is designed to work as both a standalone solution or integrated with the Grifols fully automated blood typing technology, the DG Gel system
Clinical Catch-Up: March 8-12
3/15/2021It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
BioSpace Global Roundup, March 11
3/11/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
Grifols accelerates its innovation efforts to promote its strategy of long-term growth and continue executing its plan for sustained margin expansion
Grifols fosters world's first scientific journal specialized in blood plasma
- Plasmatology aims to become the reference publication for plasma science, bringing together the discipline's knowledge, research and scientific advances that until now lacked a specialized journal